AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (827.2 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Publishing Language: Chinese | Open Access

Research progress of RNA alternative splicing mechanisms and their roles in cancer therapy

School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198
Institute of Translational Medicine, China Pharmaceutical University, Nanjing 210009, China
Show Author Information

Abstract

Alternative splicing (AS), a critical mechanism in gene expression regulation, is essential for cellular physiological processes such as proliferation, metabolism, and apoptosis via generating diverse mRNA isoforms and expanding protein diversity. In the field of oncology, AS has been significantly implicated in the regulation of various biological processes involved in tumorigenesis and cancer progression. Specific mutations or expression changes in splicing factors, such as SF3B1, SRSF2, and U2AF1, play key roles in multiple types of cancer. This review summarizes novel therapeutic strategies for cancer targeting alternative splicing, including inhibiting spliceosome components, antisense oligonucleotide (ASO) therapy, and approaches to overcome drug resistance and immune evasion in cancer. These strategies, which modulate the activity of splicing factors and RNA-modifying enzymes, show promise in addressing chemoresistance and enhancing the efficacy of immunotherapy. This review provides a comprehensive exploration of alternative splicing mechanisms, their role in cancer, and their potential as a therapeutic target, highlighting the importance of alternative splicing in cancer research and therapy.

CLC number: R730.5 Document code: A Article ID: 1000-5048(2026)-2-155-8

References

【1】
【1】
 
 
Journal of China Pharmaceutical University
Pages 155-162

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
HUANG X, TANG M, WANG D. Research progress of RNA alternative splicing mechanisms and their roles in cancer therapy. Journal of China Pharmaceutical University, 2026, 57(2): 155-162. https://doi.org/10.11665/j.issn.1000-5048.2005022401

384

Views

3

Downloads

0

Crossref

0

CSCD

Received: 24 February 2005
Published: 25 April 2026
© 2026 The Editorial Office of Journal of China Pharmaceutical University

This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).